Shots:
- Crescent granted Kelun exclusive rights to research, develop, manufacture & commercialize CR-001 in Greater China, while Kelun granted Crescent similar exclusive rights for SKB105 globally (excl. Greater China)
- Kelun will receive $80M upfront, ~$1.25B in milestones, tiered mid–single to low-double-digit royalties & potential change-of-control payments, while Crescent will get $20M upfront, ~$30M in milestones & tiered low to mid-single-digit royalties
- Alliance will incl. monotx. development & also evaluation of their combination, allowing each company to independently pursue additional CR-001 combinations; both candidates are expected to enter P-I/II monotx. trials for solid tumors in Q1’26
Ref: Crescent | Image: Kelun-Biotech & Crescent |Press Release
Related News: Kelun-Biotech Reports P-III (OptiTROP-Lung05) Trial Data on Sacituzumab Tirumotecan + Keytruda for PD-L1-Positive NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
